Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunotherapy in patients with early dMMR rectal cancer (Danish DCCG phase II trial)
2022-500646-14-00Phase 2Authorised
- Sponsor
- University Hospital Odense
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in rectal cancer, sponsored by University Hospital Odense. Primary endpoint: Clinical complete response rate at day 93. Planned start Jul 2022; status: authorised.
02
Drugs
nivolumabipilimumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2022-500646-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500646-14-00.